NBIX Neurocrine Biosciences Inc.

95.78
-1.07  -1%
Previous Close 96.85
Open 98.38
Price To Book 18.14
Market Cap 8,771,475,028
Shares 91,579,401
Volume 1,037,250
Short Ratio
Av. Daily Volume 637,214
Stock charts supplied by TradingView

NewsSee all news

  1. Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019.

  2. Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

    SAN DIEGO, Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine)

  3. Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with

  4. Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

    SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer. Boyer

  5. Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

    SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initiation 2Q/3Q 2019.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - children
Pivotal trial to be initiated pending talks with FDA in 3Q 2019.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
INGREZZA
Tardive dyskinesia
PDUFA date April 26, 2020.
Opicapone
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
NDA filing announced August 5, 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 trial ongoing. Evaluating next steps.
INGREZZA - T-Force PLATINUM
Tourette syndrome - pediatric

Latest News

  1. Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019.

  2. Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

    SAN DIEGO, Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine)

  3. Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with

  4. Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

    SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer. Boyer

  5. Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

    SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first

  6. Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly served as Acting Administrator for

  7. Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy, Chief